Using Pharma2000 to engineer Protein-derived Therapeutics
- All the diabetes symptoms explained.
- shop at an online pharmacy confidently
- Pharmaceutical Quality Procedures
THE BUSINESS MODEL
The company was created to meet certain commercial objectives:
- Reduce time to product emergence/sale -- years to months;
- Reduce cost in producing drug candidates;
- Reduce risk in finding novel non-toxic potent products -- use evolution as a silent partner;
- Make money where all the big biotech money has been made - proteins.
- Apply normal commercial imperatives: strong management, speed, first-mover advantage, low-cost production, profits over revenues, reputation.
The result is a new kind of biotechnology enterprise suitable for today's markets.
THE ADVANTAGE OF BIOLOGICALS
The genomics-proteomics revolution of the 1990's led to an increasing focus on identifying or designing small molecule drugs and creating small molecule libraries of potential drugs. Most of these compounds are intrinsically toxic, antigenic or pharmaco-kinetically unsuitable.
2000 Pharmaceuticals builds on the technology developments but is returning to biotech's base in biologicals.
The advantages of a business built on biologicals include:
- both inhibitors and agonists can be isolated;
- assay 'hits' are natural, less likely to be antigenic or toxic
- leads require some manipulation, but are unlikely to require lengthy and costly optimization;
- assay 'hits' may even turn out to be the drug itself;
- compounds are likely to have structure;
- compound libraries can be custom-designed to be relevant to the clinical question and can be adjusted in size and complexity;
- all the really big biotech sellers to date have been biologicals and protein-based.
MELBOURNE - BIOTECH CENTRE OF AUSTRALIA
Australia is strong in biomedical research with a large number of word-renowned medical research institutes, the majority of which are located in Melbourne. Both Federal and State Governments have invested heavily in the local biotech industry.
Supportive Political Environment: The Federal Government offers long-term financial support for Biotechnology, and the Victorian State Government has made a commitment to establishing Melbourne as one the World's top five biotechnology locations by 2010.
Melbourne Research Precincts
Victoria is home to the internationally renowned research organizations such as the Baker Heart Research Institute, the Walter and Eliza Hall Institute for Medical Research ('WEHI'), the Howard Florey Institute of Experimental Physiology and Medicine ('HFI'), the Ludwig Institue for Cancer Research ('LICR'), Monash University, and the University of Melbourne.
Key research precincts located in Melbourne and its surrounds include...
Alfred Medical Research Precinct (AMREP)
Located less than 5km from the CBD, the AMREP precinct is the newest purpose-designed centre of research and education excellence. This is where 2000 Pharmaceuticals has located its laboratories at the Baker Heart Research Institute. In total 500 researchers are located in the precinct and other research institutions include the MacFarlane Burnett Centre for Medical Research, Monash University and the Alfred Hospital. In addition there are also several other leading biotech companies located in the precinct including: Starpharma, Cytopia and ESI.
Parkville, Melbourne CBD
This is major centre for medical and bioscientific research includes the University of Melbourne and the RMIT University. Research Institutes include the LICR, CSIRO division of Health Sciences, Murdoch Children's Research Institute, WEHI and the HFI. This is also the location for the $400 million Bio21 development.
Monash Health Research Precinct (MHRP)
This precinct is currently being developed 20km south of Melbourne in Clayton. The MHRP and surrounding facilities at Monash University and CSIRO provide a focus for biomedical and biotechnology research. The research precinct currently includes; Monash Institute of Public Health, Price Henry's Institute for Medical Research, Monash Institute for Reproduction and Development, and again several biotech companies.
Austin Biomedical Alliance Precinct (A&RMC)
Located in the Melbourne suburb of Heidelberg, this research precinct includes such well-known Institutes such as the Ludwig Institute for Cancer Research (Clinical Division), Austin Research Institute and LaTrobe University. Over 1000 researchers are located here and in August 2000 the precinct was awarded a $320 million grant by the Federal Government to aid its expansion.
Clinical Trials Support
The Clinical Trials Victoria (CTV) project recently received an $8million grant. The CTV project brings together a number of local Institutes and health care providers to establish a world-class clinical trial capability to facilitate the development of new drug therapies to combat major diseases. The members of CTV include the Centre for Development of Cancer Therapeutics, Neurosciences Victoria, Melbourne Health as well as the Alfred Hospital, Monash University and the Baker Heart Research Institute.
Conveniently for 2000 Pharmaceuticals, the CTV will be based at the Alfred Hospital where, in partnership with the BHRI and Monash University, a 24 bed phase 1 inpatient facility will enable studies in healthy volunteers and specific patient groups.